International Alport Syndrome Meeting Report Published

KFOC, Pedersen Family and Partners award two new 2014 Alport Syndrome Research Grants

Dr. Adeera Levin Awarded Kidney Foundation of Canada’s 2014 Medal for Research Excellence

First Nations Adults with Diabetes Have More than Double the Risk of End-Stage Kidney Disease

Dr. Marcello Tonelli Awarded 2013 Medal for Research Excellence for Changing Nephrology Practice in Canada and Beyond

Paying Living Kidney Donors May Be Cost-Effective and Help Prolong Lives

The Kidney Foundation congratulates Dr. Andreas Laupacis on being awarded the inaugural CIHR Barer-Flood Prize in Health Services and Policy Research

New Research to Discover a Cure for Rare Kidney Disease

CSN Announces Editor in Chief of New Journal

Dr. Adeera Levin appointed President of the International Society of Nephrology

Sugary Drinks May Increase Risk of Kidney Stones

Launch of new Canadian National Transplant Research Program

Alberta Researchers Receive Top Achievement in Health Research Award

Kidney Foundation of Canada Helps Fund World’s First Gene Therapy Clinical Trial for Fabry Disease

First-of-Its-Kind Canadian Project to Chart the Future of Dialysis Research

Lead Investigator on Landmark Walkerton Health Study Awarded 2012 Medal for Research Excellence

New Drug Shows Hope for ADPKD Treatment

New Findings Debunk Long-Held Theory that Kidney Disease is Part of the Normal Aging Process

The Kidney Foundation of Canada partners with Kidney Cancer Canada and Government to support national research network

Sun, 11 Nov 2012

New Drug Shows Hope for ADPKD Treatment

November 11, 2012 - Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly inherited disease of the kidneys, yet there are few known effective treatments. Results of a Phase III Clinical Trial presented at the November 2012 American Society of Nephrology (ASN) annual meeting indicate the tide may be turning.

In ADPKD, many cysts form in the kidney, becoming large and fluid-filled. Over time, pressure from these cysts slowly damages kidney tissue. Painful and often causing hypertension, ADPKD leads to end-stage kidney disease (renal failure) in 50% of diagnosed cases.

Early studies indicated that V2-receptor antagonists can prevent cyst growth and slow the deterioration of kidney function. The V2-receptor antagonists are a form of treatment which targets vasopressin, a hormone that enables water absorption by the kidney and plays an important role in proper hydration. When present in high levels, however, vasopressin can cause high blood pressure.

At the most recent ASN meeting, Otsuka Pharmaceuticals Co., Ltd. announced encouraging clinical trial results for tolvaptan, a drug that works through the V2- receptor. Tolvaptan showed a decline in kidney cyst growth, a slowed decline in kidney function, and reduced risk of hypertension. Participants receiving tolvaptan, however, did report discontinuing treatment due to adverse events, such as excessive thirst related to aquaresis (increased urination that does not affect the body’s electrolyte metabolism), and other side effects unrelated to the regular symptoms of ADPKD.

The Kidney Foundation of Canada has funded research related to the V2-receptor by Drs. Bichet and Bouvier. Dr. Daniel Bichet, a recipient of the Foundation’s Medal for Research Excellence, is a nephrologists at Montreal’s Sacré-Cœur Hospital and at the Université de Montréal.  Dr. Michel Bouvier is a Principal Investigator with the Université de Montréal’s Immunology and Cancer Research Institute.

New England Journal of Medicine article on the clinical trial:
http://www.nejm.org/doi/full/10.1056/NEJMoa1205511?query=OF#t=article